Former Chief Medical Officer · Arbutus Biopharma Corp (ABUS)

Karen Sims

FY2024 is the first fiscal year CompBrief holds for Karen Sims as a named executive officer of Arbutus Biopharma; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,697,375

Salary $490,000Stock awards $242,400

4th of 4 named executive officers at Arbutus Biopharma by FY2024 total.

4 named officers on file for Arbutus Biopharma, FY2024

Karen Sims’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Arbutus Biopharma’s whole pay program stands against its peers

  • Arbutus Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABUS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2025 (DEF 14A).

Free

Get Karen Sims’s full pay file as a PDF — free

More than this page: up to 10 years of Karen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Karen Sims compensation by year

Arbutus Biopharma Summary Compensation Table · the one fiscal year held
In US dollars, as Arbutus Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$490,000
Bonus$0
Stock awards$242,400
Option awards$751,725
Non-equity incentive$196,000
Pension and deferred compensation$0
All other$17,250
Total$1,697,375

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 4, 2025, accession 0001140361-25-012305, and prior-year filings.

How this page was built: the Arbutus Biopharma Corp filed document, accession 0001140361-25-012305. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU101,000$330,270—
RSU19,267$63,003—
Option319,754—$2.40
Option1,662—$4.33
Option23,333—$2.81
Option31,308—$2.90
Option99,226—$2.26

Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Arbutus Biopharma’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Michael McElhaughFormer Interim President and Chief Executive Officer$2,110,083
David HastingsFormer Chief Financial Officer$1,825,846
Michael SofiaFormer Chief Scientific Officer$1,820,054
Karen Sims · this pageFormer Chief Medical Officer$1,697,375

The full Arbutus Biopharma compensation record

free company brief

This page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Karen Sims's compensation dossier · One-time report. No refunds.